SBIR-STTR Award

Integrated Molecular Diagnostic System for the Point-Of-Care
Award last edited on: 3/28/19

Sponsored Program
STTR
Awarding Agency
NIH : NIAID
Total Award Amount
$482,810
Award Phase
2
Solicitation Topic Code
-----

Principal Investigator
Huimin Kong

Company Information

BioHelix Corporation

500 Cummings Suite 5550
Beverly, MA 01915
   (978) 927-5056
   information@biohelix.com
   www.biohelix.com

Research Institution

Boston University

Phase I

Contract Number: 1R41AI092913-01
Start Date: 9/30/11    Completed: 8/31/13
Phase I year
2011
Phase I Amount
$241,885
This STTR-AT-NIAID seeks to develop an integrated nucleic acid system based on research done by Catherine Klapperich's laboratory at Boston University. The BU lab-on-a-chip includes a micro solid phase extraction (
Public Health Relevance:
This Phase I STTR-AT-NIAID project seeks proof-of-concept project will focus on the most abundant sexually transmitted disease (STD) pathogens: Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG). The scientific literature clearly shows that molecular testing is the most sensitive means of detecting CT and NG and the molecular CT/NG high throughput screening market is currently valued at over $300M/year. Moreover, CDC urges STD clinics to test patients with POC tests if health care workers suspect these patients are unlikely to return to the STD clinic to learn the results of the test. Unfortunately, there are no point-of-care (POC) CT NG molecular tests, and existing POC molecular testing systems like the GeneXpert are too costly for use in STD clinics. This proposed project would seek to remedy to this short coming. We propose to develop a low-cost POC molecular diagnostic system using a design developed by Dr. Catherine Klapperich's laboratory at Boston University (BU). Although the current BU disposable can perform our proprietary isothermal amplification reactions, it does not allow for low cost, instrument-free detection of amplification products;i.e., a fluorescence microscope can be used to detect product formation but this is not a commercially viable option. The device we envisage for Phase I will incorporate a lateral flow strip as a means of detecting the presence or absence of nucleic acid amplification products by simple visual inspection. BioHelix has experience in developing molecular tests using lateral flow based detection.

Thesaurus Terms:
Assay;Bedside Testings;Bioassay;Biologic Assays;Biological Assay;Boston;Buffers;Cdc;Centers For Disease Control;Centers For Disease Control And Prevention;Centers For Disease Control And Prevention (U.S.);Chemistry;Chlamydia Trachomatis;Client;Clinic;Clinical;Cytolysis;Dna;Dna Helicases;Dna Unwinding Proteins;Dna Amplification;Dna Unwinding Enzyme;Deoxyribonucleic Acid;Detection;Device Designs;Devices;Diagnostic;Engineering;Eye;Eyeball;Flaps;Gonococcus;Hand;Health Care Providers;Health Personnel;Healthcare Providers;Healthcare Worker;High Throughput Assay;Housing;Island Flaps;Loinc Axis 4 System;Lab On A Chip;Laboratories;Lateral;Learning;Liquid Substance;Literature;Lysis;Manufacturer;Manufacturer Name;Marketing;Microfluidic Device;Microfluidic Lab-On-A-Chip;Microfluidic Microchips;Molecular;Movement;N. Gonorrhoeae;N.Gonorrhoeae;Niaid;National Institute Of Allergy And Infectious Disease;Neisseria Gonorrhoeae;Nucleic Acids;Patients;Phase;Point-Of-Care Systems;Polymerase Chain Reaction;Process;Reaction;Reader;Reagent;Research;Rickettsia Trachomae;Risk;Sttr;Sampling;Sexually Transmitted Diseases;Sexually Transmitted Disorder;Sexually Transmitted Infection;Small Business Technology Transfer Research;Solid;Solutions;Staging;Surgical Flaps;System;Technical Expertise;Technology;Temperature;Test Result;Testing;Tube;Uv Laboratory Microscope;Ultraviolet Microscopes;United States Centers For Disease Control;United States Centers For Disease Control And Prevention;Universities;Urine;Urine Urinary System;Validation;Venereal Diseases;Venereal Disorders;Venereal Infections;Vent;Visual;Work;Base;Body Movement;Commercialization;Cost;Design;Designing;Experience;Fluid;Fluorescence Microscope;Fluorescence/Uv Microscope;Fluorescent Microscope;Health Care Personnel;Health Care Worker;Health Provider;Healthcare Personnel;Helicase;High Throughput Screening;Inhibitor;Inhibitor/Antagonist;Instrument;Internal Control;Laboratory Fluorescence Light Microscope;Liquid;Medical Personnel;Micro-Total Analysis System;Mu-Tas;Pathogen;Point Of Care;Point Of Care Testing;Prototype;Treatment Provider

Phase II

Contract Number: 5R41AI092913-02
Start Date: 9/30/11    Completed: 8/31/13
Phase II year
2012
Phase II Amount
$240,925
This STTR-AT-NIAID seeks to develop an integrated nucleic acid system based on research done by Catherine Klapperich's laboratory at Boston University. The BU lab-on-a-chip includes a micro solid phase extraction (